# Rajiv Mahadevan

> Rajiv Mahadevan is the co-founder and CEO of Attune Neurosciences, a San Francisco neurotechnology company building what it calls the world's first wearable, non-invasive ultrasound system for deep brain therapy. A UC Berkeley molecular biologist turned Stanford MBA, he spent two decades inside biotech and precision-medicine companies - 23andMe, Novo Nordisk, and his own venture Applied Immunology, which was acquired by Precision Medicine Group - before turning his attention to the skull. Attune's headband-shaped device aims low-intensity focused ultrasound at deep brain structures with MRI-guided precision, and it is backed by venture investors, the NIH, and the U.S. Special Operations Command.

- **Role:** Co-founder and CEO at Attune Neurosciences, Inc.
- **Organizations:** Attune Neurosciences, Inc., Tactile Therapeutics, Inc., Aliso Ventures, Precision Medicine Group, Applied Immunology, 23andMe, Novo Nordisk
- **Nationality:** American
- **Education:** BA, Molecular & Cell Biology, University of California, Berkeley, MBA, Stanford University Graduate School of Business
- **Known for:** Co-founded and led Applied Immunology to an acquisition by Precision Medicine Group, Founded Attune Neurosciences and built a wearable transcranial focused-ultrasound platform, Secured funding from venture investors, the NIH, and the U.S. Special Operations Command

## Career timeline

- **1997** — Earns a BA in Molecular & Cell Biology from UC Berkeley
- **2003** — Completes an MBA at Stanford Graduate School of Business
- **2000s** — Holds business development roles at Novo Nordisk and 23andMe
- **2010s** — Co-founds and leads Applied Immunology as CEO; company later acquired by Precision Medicine Group
- **2016** — Becomes Managing Director at Precision Medicine Group
- **2018** — Joins the board of Bionure
- **2019** — Founds Attune Neurosciences; becomes an investment partner at Aliso Ventures
- **2020** — Takes the CEO role at Attune Neurosciences
- **2021** — Co-founds Tactile Therapeutics, Inc.
- **2023** — Attune's wearable ultrasound device enters human safety studies (ATTN201 / NCT05895474)

## Achievements

- Co-founded and led Applied Immunology to an acquisition by Precision Medicine Group
- Founded Attune Neurosciences and built a wearable transcranial focused-ultrasound platform
- Secured funding from venture investors, the NIH, and the U.S. Special Operations Command
- Advanced a non-invasive deep-brain stimulation device into human safety trials

## Latest updates

- **2023-05** — Attune's ATTN201 wearable ultrasound device begins a human safety study of central medial thalamus stimulation (NCT05895474).
- **2025-01** — Attune Neurosciences secures additional grant funding to advance its non-invasive neurostimulation program.

## Links

- Website: https://attuneneuro.com
- LinkedIn: http://www.linkedin.com/in/rajiv-mahadevan-86958

---

Profile page: https://yespress.io/rajiv-mahadevan
Published by YesPress — https://yespress.io
Last updated: 2026-06-21